NCT06703398 2025-12-23
MIZAR-003
Shanghai Juncell Therapeutics
Phase 2 Recruiting
Clinical Trials
10 trialsNCT03645928 2025-06-19
LN-144
Iovance Biotherapeutics, Inc.
Phase 2 Recruiting
NCT00505635 2020-09-24
Biochemotherapy With Temozolomide for Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00707161 2017-03-31
Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma
University of Utah
Phase 2 Terminated
NCT02285413 2016-05-04
Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients
Radboud University Medical Center
Phase 2 Completed
NCT00885534 2015-05-06
Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00492505 2014-01-10
Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00004141 2013-09-05
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma
University of Chicago
Phase 2 Completed
NCT00002669 2012-07-02
Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00083252 2007-06-08
Study of Talabostat and Cisplatin in Advanced Melanoma
Point Therapeutics
Phase 2 Completed